The rollout of new drugs like Sovaldi, the pricing revelations at Turing Pharmaceuticals, and the Epipen episode have fed both concerns about pharmaceutical pricing and problematic proposals to address these concerns. Three-quarters of Americans say they want more government interventions to address public alarm around drug prices. Clearly there is widespread unease about the pricing of treatments, availability of lower-cost generics, competition in the pharmaceutical sector, and the ability for patients to access the drugs they need.